Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.63 |
| ▸ | RAB9A | P51151 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | KRAS | P01116 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Btzo-1 SCHEMBL29394317 | 1.00 | MIF (1.00) | MIFGABRA1KDM4ENPC1RAB9A | |
| SCHEMBL13199864 | 0.91 | MIF (0.83) | MIFGABRA1KDM4ENPC1RAB9A | |
| SCHEMBL2958852 | 0.83 | MIF (0.71) | MIFGABRA1KDM4ENPC1RAB9A | |
| SCHEMBL2964187 | 0.83 | MIF (0.70) | MIFGABRA1KDM4ENPC1RAB9A | |
| SCHEMBL2956589 | 0.83 | MIF (0.70) | MIFGABRA1KDM4ENPC1RAB9A | |
| SCHEMBL2961958 | 0.83 | MIF (0.70) | MIFGABRA1KDM4ENPC1RAB9A | |
| SCHEMBL2964512 | 0.83 | MIF (0.70) | MIFGABRA1KDM4ENPC1RAB9A | |
| SCHEMBL2956287 | 0.83 | MIF (0.70) | MIFGABRA1KDM4ENPC1RAB9A | |
| SCHEMBL2961600 | 0.83 | MIF (0.70) | MIFGABRA1KDM4ENPC1RAB9A | |
| SCHEMBL2962153 | 0.83 | MIF (0.70) | MIFGABRA1KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074976-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING PERIPHERAL NERVE INJURY | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2025-03-06 | — | — | US | disclosed |
| US-12133720-B2 | Methods and compositions for restoring homeostatic capacity of a subject | Palo Alto Investors LP (US) | 2024-11-05 | — | — | US | disclosed |
| EP-4393507-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING PERIPHERAL NERVE INJURY | National University Corporation Hokkaido University (JP) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023007779-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING PERIPHERAL NERVE INJURY | 国立大学法人北海道大学 | 2023-02-02 | — | — | WO | disclosed |
| WO-2022190064-A1 | METHODS FOR IDENTIFYING SUBJECTS WITH BETACORONAVIRUS INFECTIONS WHO ARE AT RISK OF ACUTE RESPIRATORY SYNDROME AND METHODS FOR THE TREATMENT OF SAME | VEXO PHARMACEUTICALS DMCC (AE) | 2022-09-15 | — | — | WO | disclosed |
| US-20210076956-A1 | Methods and Compositions for Restoring Homeostatic Capacity of a Subject | Palo Alto Investors LP | 2021-03-18 | — | — | US | disclosed |
| US-10835134-B2 | Methods and compositions for restoring homeostatic capacity of a subject | PALO ALTO INVESTORS (US) | 2020-11-17 | — | — | US | disclosed |
| US-20150359888-A1 | Methods and Compositions for Restoring Homeostatic Capacity of a Subject | PALO ALTO INVESTORS | 2015-12-17 | — | — | US | disclosed |
| US-9044483-B2 | Cell death inhibition by macrophage migration inhibitory factor and a binding substance thereto | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2015-06-02 | — | — | US | disclosed |
| US-9044483-B2 | Cell death inhibition by macrophage migration inhibitory factor and a binding substance thereto | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2015-06-02 | — | — | US | disclosed |
| US-20080160553-A1 | Method of preparing heart muscle cells and method of searching for remedy for heart diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20060052371-A1 | 1,3-Benzothiazinone derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-09 | — | — | US | disclosed |
| US-20060034832-A1 | Cell death inhibitor | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 2006-02-16 | — | — | US | disclosed |
| EP-1568697-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-08-31 | — | — | EP | disclosed |
| EP-1500402-A1 | CELL DEATH INHIBITOR | Takeda Pharmaceutical Company Limited (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-6794383-B2 | Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-09-21 | — | — | US | disclosed |
| US-20030186971-A1 | Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| US-20030175847-A1 | Method of preparing heart muscle cells and method of searching for remedy for heart diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1325918-A1 | HEART MUSCULAR CELL APOPTOSIS INHIBITORS AND REMEDIES/PREVENTIVES FOR HEART DISEASES | Takeda Chemical Industries, Ltd. (JP) | 2003-07-09 | — | — | EP | disclosed |
| EP-1295936-A1 | METHOD OF PREPARING HEART MUSCLE CELLS AND METHOD OF SEARCHING FOR REMEDY FOR HEART DISEASES | Takeda Chemical Industries, Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186971-A1 | Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases | TNNI3, TNNT2, BAX | MIF 2269/4885GABRA1 4587/4885KDM4E 1355/4885 |
| US-20060034832-A1 | Cell death inhibitor | MIF, TNFSF11, PDCD6IP | MIF 1/4885GABRA1 4356/4885KDM4E 3351/4885 |
| US-20060052371-A1 | 1,3-Benzothiazinone derivatives, process for producing the same and use thereof | MIF, FOXM1, HMGB3 | MIF 1/4885GABRA1 2701/4885KDM4E 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.